dc.contributorUniversidade de São Paulo (USP)
dc.contributorUniversidade Federal de São Paulo (UNIFESP)
dc.contributorFac Med ABC
dc.contributorHosp Ninos Luis Calvo Mackenna
dc.contributorHosp Ninos Dr Ricardo Gutierrez
dc.contributorHosp Juan P Garrahan
dc.contributorLouisiana State Univ
dc.contributorHosp Nacl Ninos Dr Carlos Saenz Herrera
dc.contributorInst Nacl Pediat
dc.contributorUniv Antioquia
dc.contributorUniv La Frontera
dc.creatorCondino-Neto, A.
dc.creatorCosta-Carvalho, B. T. [UNIFESP]
dc.creatorGrumach, A. S.
dc.creatorKing, A.
dc.creatorBezrodnik, L.
dc.creatorOteastro, M.
dc.creatorLeiva, L.
dc.creatorPorras, O.
dc.creatorEspinosa-Rosales, F. J.
dc.creatorFranco, J. L.
dc.creatorSorensen, R. U.
dc.date.accessioned2016-01-24T14:37:14Z
dc.date.available2016-01-24T14:37:14Z
dc.date.created2016-01-24T14:37:14Z
dc.date.issued2014-05-01
dc.identifierAllergologia Et Immunopathologia. Barcelona: Elsevier Doyma Sl, v. 42, n. 3, p. 245-260, 2014.
dc.identifier0301-0546
dc.identifierhttp://repositorio.unifesp.br/handle/11600/37724
dc.identifier10.1016/j.aller.2012.09.006
dc.identifierWOS:000337266200013
dc.description.abstractAntibodies are an essential component of the adaptative immune response and hold long-term memory of the immunological experiences throughout life. Antibody defects represent approximately half of the well-known primary immunodeficiencies requiring immunoglobulin replacement therapy. in this article, the authors review the current indications and therapeutic protocols in the Latin American environment. Immunoglobulin replacement therapy has been a safe procedure that induces dramatic positive changes in the clinical outcome of patients who carry antibody defects. (C) 2012 SEICAP Published by Elsevier Espana, S.L. All rights reserved.
dc.languageeng
dc.publisherElsevier B.V.
dc.relationAllergologia Et Immunopathologia
dc.rightshttp://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy
dc.rightsAcesso restrito
dc.subjectImmunoglobulin replacement therapy
dc.subjectIntravenous immunoglobulin
dc.subjectSubcutaneous immunoglobulin
dc.subjectGuidelines
dc.subjectPrimary immunodeficiency
dc.subjectLatin America
dc.titleGuidelines for the use of human immunoglobulin therapy in patients with primary immunodeficiencies in Latin America
dc.typeArtigo


Este ítem pertenece a la siguiente institución